Harmony Biosciences opened lower at $34.18, compared with its previous close of $34.22. In the last trading session, the stock traded between $33.19 and $34.26. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Harmony Biosciences is now worth
$ 79.48
Resulting in a loss of
$ 20.52 (20.52%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 7 Analysts
Buy
71.43%
Hold
14.29%
Sell
14.29%
Markets Today
Today's Change
$-0.43 (-1.24%)
Day High
$34.26
Day Low
$33.19
Day Open
$34.18
Prev Close
$34.22
Volume
7,29,966
1W Return
-1.92%
1M Return
-11.64%
3M Return
-14.43%
6M Return
11.98%
1Y Return
2.47%
Fundamentals
Market Cap ($ Mn)
1,985
PE Ratio
12.65
PB Ratio
2.28
PEG Ratio
1.23
ROE
20.57%
ROCE
22.41%
EPS (TTM)
$0.82
Investment Returns
1 Week
-1.92%
1 Month
-11.64%
3 Months
-14.43%
6 Months
11.98%
9 Months
-7.64%
Financials
Quarterly
All values in $ Mn
200.5
Jun 25
239.5
Sep 25
243.8
Dec 25
215.4
Mar 26
261.3
Jun 26
268.9
Sep 26
Updates
12Nov
HC Wainwright reiterates Buy on Harmony Biosciences, keeps $55 target
HC Wainwright & Co. reiterated a Buy rating on Harmony Biosciences Holdings. Analyst Patrick R. Trucchio maintained the $55 price target. The rating action reflects unchanged confidence in the stock's outlook.
Today
4Nov
Harmony Biosciences Q3FY26 Results: Revenue rises 12.5% YoY to $269 million
Net revenue rose 12.5% YoY to $269 million in Q3FY26. Net income declined to $48 million due to royalty and milestone charges. Full-year guidance affirmed at $1.000 billion to $1.040 billion. WAKIX adds 400 net patients, on track to exceed $1 billion annual revenue. CEO transition announced; Peter Anastasiou to succeed Jeffrey Dayno in Jan 2027.
8 days ago
20Oct
Harmony Biosciences to report Q3FY27 results on November 4
Reports third quarter 2026 financial results on November 4, 2026. Conference call scheduled for 8:30 am ET on the same day. Webcast available via investor relations website.
23 days ago
12Oct
Harmony Biosciences names Peter Anastasiou as CEO effective January 2027
Peter Anastasiou appointed President and CEO effective January 1, 2027. Jeffrey M. Dayno retiring after nine-year tenure; steps down from Board Dec 31, 2026. Full-year 2026 WAKIX net revenue guidance reaffirmed at $1.0 billion to $1.04 billion. BP-205 MAD study data expected in Q4 2026; no change in milestone timing.
1mo ago
27Aug
Harmony Biosciences to present at 2026 Cantor Global Healthcare Conference
Harmony Biosciences management to speak at 2026 Cantor Global Healthcare Conference. Fireside chat scheduled for September 10, 2026, at 10:20 am ET in New York. Webcast available via the company's investor relations website.
2mo ago
4Aug
Harmony Biosciences affirms FY26 sales guidance of $1.000B-$1.040B
Harmony Biosciences Holdings reaffirms its FY26 sales guidance of $1.000 billion to $1.040 billion, matching the $1.020 billion market estimate. The stable outlook reflects consistent expectations for revenue performance.
